These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 24413263)

  • 1. Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history.
    Cescon A; Chan K; Raboud JM; Burchell AN; Forrest JI; Klein MB; Loutfy MR; Machouf N; Montaner JS; Tsoukas C; Hogg RS; Cooper C;
    AIDS; 2014 Jan; 28(1):121-7. PubMed ID: 24413263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.
    Di Martino V; Rufat P; Boyer N; Renard P; Degos F; Martinot-Peignoux M; Matheron S; Le Moing V; Vachon F; Degott C; Valla D; Marcellin P
    Hepatology; 2001 Dec; 34(6):1193-9. PubMed ID: 11732009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food insecurity may lead to incomplete HIV viral suppression and less immune reconstitution among HIV/hepatitis C virus-coinfected people.
    Aibibula W; Cox J; Hamelin AM; Moodie E; Naimi AI; McLinden T; Klein MB; Brassard P
    HIV Med; 2018 Feb; 19(2):123-131. PubMed ID: 29094807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus.
    Hull MW; Rollet K; Odueyungbo A; Saeed S; Potter M; Cox J; Cooper C; Gill J; Klein MB;
    Clin Infect Dis; 2012 Jun; 54(12):1798-805. PubMed ID: 22460964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals.
    Gillis J; Smieja M; Cescon A; Rourke SB; Burchell AN; Cooper C; Raboud JM;
    Antivir Ther; 2014; 19(3):309-17. PubMed ID: 24429380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.
    Lincoln D; Petoumenos K; Dore GJ;
    HIV Med; 2003 Jul; 4(3):241-9. PubMed ID: 12859323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database.
    Zhou J; Dore GJ; Zhang F; Lim PL; Chen YM;
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1510-8. PubMed ID: 17645479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
    Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
    Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
    Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
    Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment.
    Hua L; Andersen JW; Daar ES; Glesby MJ; Hollabaugh K; Tierney C
    AIDS; 2013 Nov; 27(17):2725-34. PubMed ID: 23921611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
    Rockstroh JK; Peters L; Grint D; Soriano V; Reiss P; Monforte Ad; Beniowski M; Losso MH; Kirk O; Kupfer B; Mocroft A;
    J Hepatol; 2013 Aug; 59(2):213-20. PubMed ID: 23583272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.
    May MT; Justice AC; Birnie K; Ingle SM; Smit C; Smith C; Neau D; Guiguet M; Schwarze-Zander C; Moreno S; Guest JL; Monforte Ad; Tural C; Gill MJ; Bregenzer A; Kirk O; Saag M; Sterling TR; Crane HM; Sterne JA
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):348-54. PubMed ID: 25848927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.
    Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM
    J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
    J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study.
    Cescon A; Patterson S; Chan K; Palmer AK; Margolese S; Burchell AN; Cooper C; Klein MB; Machouf N; Montaner JS; Tsoukas C; Hogg RS; Raboud JM; Loutfy MR;
    PLoS One; 2013; 8(12):e83649. PubMed ID: 24391803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus.
    Saadoun D; Aaron L; Resche-Rigon M; Pialoux G; Piette JC; Cacoub P;
    AIDS; 2006 Apr; 20(6):871-7. PubMed ID: 16549971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coinfection with hepatitis C virus among HIV-positive people in the Kathmandu Valley, Nepal.
    Poudel KC; Palmer PH; Jimba M; Mizoue T; Kobayashi J; Poudel-Tandukar K
    J Int Assoc Provid AIDS Care; 2014; 13(3):277-83. PubMed ID: 24056798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.